Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy: Perspectives From the Treasure Database

Basit Öğe Kaydı
dc.authorscopusid57202265979
dc.authorscopusid57202958234
dc.authorscopusid57211446536
dc.authorscopusid14422446100
dc.authorscopusid57397152100
dc.authorscopusid57397904700
dc.authorscopusid8392501600
dc.contributor.authorTekgöz, Emre
dc.contributor.authorÇolak, Seda
dc.contributor.authorYardımcı, Kübra G.
dc.contributor.authorKüçükşahin, Orhan
dc.contributor.authorÇınar, Muhammet
dc.contributor.authorYılmaz, Sedat
dc.contributor.authorKalyoncu, Umut
dc.contributor.authorMercan, Rıdvan
dc.date.accessioned2022-05-11T14:05:03Z
dc.date.available2022-05-11T14:05:03Z
dc.date.issued2022
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractOBJECTIVE: Because of concerns about malignancy risks, using biological disease-modifying antirheumatic drugs (bDMARDs) in patients with a history of malignancy remains a challenging issue in rheumatology practice. This study aimed to investigate bDMARD preferences of physicians when treating of rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients with a history of malignancy. METHODS: The data for this cross-sectional study were gathered from the TReasure database using a date range of December 2017 and January 2020. Biological disease-modifying antirheumatic drug preferences were analyzed for 40 RA patients and 25 SpA patients with a history of malignancy. RESULTS: The most frequently prescribed bDMARD was rituximab, which was given to 28 RA patients (70%). For 25 patients (62.5%), the time between the diagnosis of malignancy and starting on a bDMARD regimen was less than 60 months, with a median interval of 43.5 months. Among SpA patients, the preferred bDMARDs were secukinumab and etanercept, which were each administered to 7 patients (28%). For 13 SpA patients (52%), the time between the diagnosis of malignancy and starting on bDMARDs was less than 60 months, with a median interval of 97 months. CONCLUSIONS: The observed bDMARD preferences may be related to the therapeutic effects of rituximab on lymphoproliferative malignancies, the protective effects of secukinumab on tumor progression, and the short half-life of etanercept. Biological disease-modifying antirheumatic drugs should be used in RA and SpA patients with malignancy in case of high inflammatory activity. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
dc.identifier.doi10.1097/RHU.0000000000001699
dc.identifier.endpagee323
dc.identifier.issn1536-7355
dc.identifier.issue2en_US
dc.identifier.pmid34014053
dc.identifier.scopus2-s2.0-85125018602
dc.identifier.scopusqualityQ2
dc.identifier.startpagee318
dc.identifier.urihttps://doi.org/10.1097/RHU.0000000000001699
dc.identifier.urihttps://hdl.handle.net/20.500.11776/4880
dc.identifier.volume28
dc.identifier.wosWOS:000759079900010
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorMercan, Rıdvan
dc.language.isoen
dc.publisherNLM (Medline)
dc.relation.ispartofJournal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectantirheumatic agent
dc.subjectbiological product
dc.subjectcross-sectional study
dc.subjecthuman
dc.subjectneoplasm
dc.subjectphysician
dc.subjectrheumatoid arthritis
dc.subjectspondylarthritis
dc.subjectAntirheumatic Agents
dc.subjectArthritis, Rheumatoid
dc.subjectBiological Products
dc.subjectCross-Sectional Studies
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectPhysicians
dc.subjectSpondylarthritis
dc.titlePhysicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy: Perspectives From the Treasure Database
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu